๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Validation of surrogate endpoint biomarkers in prostate cancer chemoprevention trials

โœ Scribed by Bruce J Trock

Book ID
117263395
Publisher
Elsevier Science
Year
2001
Tongue
English
Weight
210 KB
Volume
57
Category
Article
ISSN
0090-4295

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

A phase II chemoprevention trial design
A phase II chemoprevention trial design to identify surrogate surrogate endpoint biomarkers in breast cancer
โœ Kapil Dhingra ๐Ÿ“‚ Article ๐Ÿ“… 1995 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 434 KB

Surrogate biomarkers for risk assessment and efficacy of potential chemopreventive agents are needed to improve the efficiency and reduce the cost of conducting chemoprevention trials. In addition to criteria of sensitivity, specificity, quantifiability, and reproducibility applicable to most potent

Prostatic intraepithelial neoplasia (PIN
Prostatic intraepithelial neoplasia (PIN) and other prostatic lesions as risk factors and surrogate endpoints for cancer chemoprevention trials
โœ David G. Bostwick; Joseph W. Aquilina ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 876 KB

The most efficient strategy for chemoprevention clinical trials are short-term studies which focus on surrogate endpoint biomarkers (SEBs) in high-risk target populations. High-grade prostatic intraepithelial neoplasia (PIN) is the most likely precursor of prostate cancer, and is found in a signific